Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086 | Director | May 10, 2017 | May 12, 2017 |
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director | May 31, 2018 | June 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXION PHARMACEUTICALS, INC.
Report date May 10, 2017 · Filed May 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 4,906 |
Reported balance
After 2017-05-10 transaction · row 1
1 source rowRow 1 · 2017-05-10 · Grant · Acquired 2,030 · Balance 4,906 F1: RSU's will vest 100% on the 1-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: RSU's will vest 100% on the 1-year anniversary of the grant date.
Krystal Biotech, Inc.
Report date May 31, 2018 · Filed June 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.29 · Expires 2028-05-31 | Direct | 7,500 |
Reported balance
After 2018-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-31 · Grant · Acquired 7,500 · Balance 7,500 F1: The options were awarded on May 31, 2018 and vest monthly over a one-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were awarded on May 31, 2018 and vest monthly over a one-year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2018 Filed Jun 4, 2018 20:49 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $10.29 | $0.00 |
DisclosureSEC source: 0001209191-18-035175 · doc4.xml · derivative · entry 1 NORBY R DOUGLAS · CIK 0001227001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-31 F1 · derivative.exercise_date: The options were awarded on May 31, 2018 and vest monthly over a one-year period. Read SEC document |
| May 09, 2018 Filed May 11, 2018 20:27 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | PurchaseCommon Stock | 9,000 | $10.42 | $93,780.00 |
DisclosureSEC source: 0001209191-18-029567 · doc4.xml · nonDerivative · entry 1 NORBY R DOUGLAS · CIK 0001227001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.31 to $10.60. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 10, 2017 Filed May 12, 2017 18:01 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 2,030 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000112 · wf-form4_149462648170771.xml · nonDerivative · entry 1 NORBY R DOUGLAS · CIK 0001227001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,906 F1 · shares: RSU's will vest 100% on the 1-year anniversary of the grant date. Read SEC document |
| September 23, 2016 Filed Sep 27, 2016 17:14 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Exercise / conversionCommon Stock, par value $.0001 per share | 1,774 | $131.97 | $234,114.78 |
DisclosureSEC source: 0000899866-16-000361 · wf-form4_147501083422588.xml · nonDerivative · entry 4 NORBY R DOUGLAS · CIK 0001227001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.66 - $132.66. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| September 23, 2016 Filed Sep 27, 2016 17:14 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Exercise / conversionCommon Stock, par value $.0001 per share | 3,724 | $131.10 | $488,216.40 |
DisclosureSEC source: 0000899866-16-000361 · wf-form4_147501083422588.xml · nonDerivative · entry 3 NORBY R DOUGLAS · CIK 0001227001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $130.56 - $131.56. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| September 23, 2016 Filed Sep 27, 2016 17:14 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Exercise / conversionCommon Stock, par value $.0001 per share | 2,800 | $130.03 | $364,084.00 |
DisclosureSEC source: 0000899866-16-000361 · wf-form4_147501083422588.xml · nonDerivative · entry 2 NORBY R DOUGLAS · CIK 0001227001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $129.35 - $130.35. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| September 23, 2016 Filed Sep 27, 2016 17:14 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Exercise / conversionCommon Stock, par value $.0001 per share | 7,202 | $128.81 | $927,689.62 |
DisclosureSEC source: 0000899866-16-000361 · wf-form4_147501083422588.xml · nonDerivative · entry 1 NORBY R DOUGLAS · CIK 0001227001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $128.35 - $129.35. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.